Running a Clinical Trial in Ethiopia: The Regulatory and Ethical Approval Pathway
Ethiopia is becoming a more credible destination for clinical research. In September 2025, the World Health Organization recognized the Ethiopian Food and Drug Authority (EFDA) as having achieved Maturity Level 3 (ML3) — including for its clinical-trial oversight function — confirming a stable, well-functioning, and internationally aligned regulatory system. For pharmaceutical sponsors, contract research organizations, academic institutions, and the domestic manufacturers building toward vaccine and biologics production, that recognition signals something important: a trial conducted in Ethiopia rests on a regulatory foundation that global partners can trust.
But credibility comes with rigor. No clinical trial involving human participants may proceed in Ethiopia without clearing two distinct gates — regulatory authorization from EFDA and ethical clearance from an authorized ethics review body. This article explains the legal framework, the dual approval pathway, the timelines a sponsor should plan for, the protections the law guarantees to participants, and the practical points where applications most often run into delay.
The legal framework
Clinical trials in Ethiopia are governed by a clear, layered framework:
Proclamation No. 1112/2019 establishes the regime. It is prohibited to conduct any clinical trial involving human subjects without the prior authorization of EFDA. The Authority reviews trial protocols on scientific, legal, and ethical grounds, controls amendments, and may inspect a study before, during, and after it runs — with the power to suspend or stop any non-compliant trial (Article 27).
Clinical Trial Directive No. 964/2023 operationalizes the Proclamation, setting the detailed requirements for protocol evaluation, monitoring, inspection, participant insurance, and the Authority's powers at each stage.
The EFDA Guideline for Clinical Trial Authorization (the current version took effect in June 2025) provides the procedural detail — the documents to submit, the review process, the timelines, and the responsibilities of every stakeholder. It applies to trials of investigational products, including new medicines, biological products and vaccines, new therapeutic regimens, diagnostic procedures, and bioequivalence studies.
The EFDA Good Clinical Practice (GCP) Guideline, aligned with WHO and ICH-GCP standards, sets the technical conduct standard.
Together, these instruments give Ethiopia a framework that is both internationally recognizable and locally enforceable.
The dual approval pathway: regulatory and ethical
Approval to run a trial in Ethiopia involves two separate review processes, and understanding how they fit together is the single most important piece of planning.
1. Ethical review. Independent ethical review safeguards the rights, safety, and well-being of participants. Approval comes from an Institutional Review Board (IRB) and/or the National Research Ethics Review Board (NRERB), with a national ethics committee reviewing trials where there is no recognized institutional committee, where the institutional committee cannot perform the review to standard, or where the trial runs across multiple sites. EFDA's approval letter from the NRERB and/or IRB, together with the approved protocol, must be provided to the Authority.
2. Regulatory review (EFDA). EFDA evaluates the scientific validity and safety of the proposed trial. The protocol and essential documents are reviewed by two or more experts, and the Authority may use external assessors and a National Clinical Trial Advisory Committee. A trial proceeds only after a protocol demonstrating adequate non-clinical and clinical support, sufficient resources, and conflict-of-interest disclosures has been evaluated and approved.
A crucial sequencing point: ethical clearance is effectively a gateway to regulatory review. EFDA's application form requires the NRERB and IRB approvals up front, and regulatory review proceeds on that basis. Sponsors should therefore build the ethics-review stage into their critical path from the very beginning — it is not a parallel track that can be run alongside the regulatory submission. (A move toward more coordinated or parallel review is under active discussion, which would shorten overall timelines; but sponsors should plan around the current sequential reality.)
The timelines a sponsor should plan for
One of the most useful features of the current EFDA guideline is that it publishes its review clocks — a transparency that ML3-level regulators are expected to provide. The key timelines:
Screening. EFDA first decides whether a submission qualifies as a clinical trial — within 7 working days for a routine application, or 4 working days for a non-routine one.
First feedback. For a duly completed routine application (with the service fee paid), first feedback comes within 45 working days. For a high-risk trial, review may extend up to 90 calendar days. For non-routine (expedited) applications, the review is no more than 30 calendar days.
Applicant responses. The applicant has six months to respond to the Authority's feedback (with notice required if more time is needed). An application can be rejected if the applicant fails to provide adequate responses across three consecutive rounds of feedback.
Amendments. Major amendments require prior approval; the Authority gives feedback on amendment applications within 15 working days. Minor amendments may be implemented once the Authority confirms their categorization in writing.
Knowing these clocks lets a sponsor build a realistic timeline — and underscores why a clean, complete, well-organized application matters: the clock runs on duly completed submissions, and incomplete applications simply lose time at screening.
An expedited pathway for urgent needs
Not every trial follows the routine clock. The guideline provides an expedited (non-routine) review for trials addressing life-threatening conditions, or where the investigational product could meet an unmet medical need — particularly during a national epidemic, a global pandemic, or similar emergency — provided the risks are reasonable in relation to the expected benefits. EFDA may also conduct joint reviews with other regulators and recognize decisions from bodies such as WHO, AVAREF, the EMA, and the US FDA. For sponsors of products already assessed by a trusted authority, this reliance capacity can meaningfully accelerate a sound decision.
What the law guarantees to participants
Ethiopia's framework places participant protection at its center, reflecting both the Proclamation and international GCP principles. The core safeguards a sponsor and investigator must honor include:
Written informed consent. Freely given, written informed consent must be obtained from every participant before participation. Where a participant cannot consent, written consent from a legally authorized representative is required; and for children aged 12–17, written assent must be sought in addition to parental or guardian consent.
The right to withdraw. A participant may withdraw at any time, without prejudice, and no data may be collected from those who refuse or withdraw.
Heightened protection for vulnerable groups. Strict conditions govern the inclusion of vulnerable participants, such as minors or pregnant and nursing women (Proclamation No. 1112/2019, Article 27).
Mandatory insurance and compensation. It is mandatory in Ethiopia to have adequate comprehensive insurance covering trial participants; sponsors pay for medical treatment of trial-related injuries, and any compensation arrangements must be disclosed to participants in the information sheet (Directive No. 964/2023, Article 13; EFDA Guideline). Importantly, insurance does not bar a participant from pursuing a negligence claim in an Ethiopian court.
Safety reporting. The principal investigator must report any serious adverse event to EFDA in writing within 48 hours, and the sponsor carries ongoing safety-evaluation and reporting obligations.
Trial registration. The sponsor must register the trial in both the Ethiopian and an internationally recognized clinical trials registry before screening and recruitment begin.
The allocation of responsibility is clear: the investigator (who must be an Ethiopia-based, qualified, registered health professional) is responsible for the proper conduct of the trial at the site and for participants' rights, health, and welfare; the sponsor carries protocol, safety, insurance, registration, and reporting obligations; the ethics body provides independent assurance that participants are protected; and EFDA holds the overarching authorization, monitoring, and enforcement powers.
Where applications stall — and how to plan around it
Drawing on how the system operates, the recurring friction points for sponsors are less about the merits of the science than about process and preparation:
Underestimating the ethics stage. Because EFDA's review effectively requires ethics approval up front, a slow ethics-review stage delays everything downstream. Build it into your critical path from day one.
Incomplete applications. The review clock runs on duly completed submissions. A protocol that clearly demonstrates non-clinical and clinical support, adequate resources, and conflict-of-interest disclosures moves through review; an incomplete one loses time at screening and through repeated feedback rounds.
Site readiness. Ethiopia does not yet operate a fully standardized national system for qualifying trial sites; the Authority assesses site readiness case by case. Confirm site qualification — and that you have a qualified, Ethiopia-based principal investigator — early.
Insurance arrangements. The mandatory insurance cover must be in place; getting the coverage and compensation terms right before submission avoids a foreseeable query.
Investigational product logistics. Investigational products may be imported only after the trial is authorized and an import permit is obtained, and must be manufactured to GMP — a sequencing point that can catch sponsors who plan importation too early.
The strategic takeaway: in Ethiopia, the binding constraint on a trial's start date is frequently the ethics-then-regulator sequence, application completeness, and site qualification — not the scientific review itself. A sponsor who plans around those realities, with a well-prepared protocol, a qualified site and investigator, ethics approval secured early, and insurance arranged, can move through the process efficiently.
Why this matters beyond any single trial
A credible clinical-trial ecosystem is foundational to Ethiopia's pharmaceutical ambitions: GCP-compliant trials are a prerequisite for developing and registering new products and for achieving WHO prequalification, and reliable bioequivalence studies are essential for the generics sector to build a competitive domestic portfolio and open export pathways. For sponsors and manufacturers, conducting trials within this recognized framework is what converts Ethiopia's regulatory standing into real market access.
How we can help
Prime Law advises sponsors, contract research organizations, investigators, and manufacturers on the full clinical-trial pathway in Ethiopia — from structuring the regulatory and ethical approval strategy and reviewing protocols for compliance, to advising on participant-protection requirements, insurance and compensation obligations, trial registration, investigational-product importation, and the conduct obligations that follow approval. Our founding partners' work on Ethiopia's pharmaceutical and regulatory framework means we understand not only what the rules require, but how they are applied in practice.
If you are planning a clinical trial in Ethiopia, write to us at info@primelaw.law.
This article is provided for general information only and does not constitute legal advice. Regulatory requirements and procedures may change; for advice on a specific trial or application, please consult qualified legal counsel.
